Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 21;9(12):e003439. doi: 10.1136/jitc-2021-003439

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Dynamics of TAA-reactive T cells under anti-PD-1 therapy correlate with clinical outcome in two independent cohorts. Disappearance of NY-ESO-1-reactive/Melan-A-reactive T cells from the circulation correlates with superior clinical outcome in two independent cohorts. Probability of overall survival (right panel) and progression-free survival (left panel) among patients with disappearing (black arm) or stable/appearing (red arm) TAA-specific T cells. Progression-free survival could not be evaluated for two patients with stable/appearing TAA-reactive T cells in cohort A and for two in cohort B. PD-1, programmed cell death protein 1; TAA, tumor-associated antigen.